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Abstract  
Background—Preeclampsia (PE) is a complex and common human-specific pregnancy 
syndrome associated with placental pathology. The human-specificity provides both intellectual 
and methodological challenges, lacking a robust model system. Given the role of imprinted 
genes in human placentation and the vulnerability of imprinted genes to loss of imprinting 
changes, there has been extensive speculation, but no robust evidence, that imprinted genes are
involved in PE. Our study aims at investigating whether disturbed imprinting contributes to PE.  
Methods—We first aimed at confirming that PE is a disease of the placenta by generating and 
analysing genome-wide molecular data on well-characterized patient material. We performed 
high-throughput transcriptome analyses of multiple placenta samples from normal and PE 
patients. Next, we identified differentially expressed genes (DEGs) in PE placenta, and 
intersected them with the list of human imprinted genes. We employed bioinformatics/statistical
analyses to confirm association between imprinting and PE, and to predict biological processes 
affected in PE. Validation included epigenetic and cellular assays. Regarding human-specificity, 
we established an in vitro invasion-differentiation trophoblast model. Our comparative 
phylogenetic analysis involved single-cell transcriptome data of human, macaque and mouse 
preimplantation embryogenesis.
Results—We found disturbed placental imprinting in PE and revealed potential candidates, 
including GATA3 and DLX5, with poorly explored imprinted status and no prior association with 
PE. Due to loss of imprinting DLX5 was upregulated in 69% of PE placentas. Levels of DLX5 
correlated with classical PE marker. DLX5 is expressed in human, but not in murine trophoblast. 
The DLX5high phenotype resulted in reduced proliferation, increased metabolism and ER stress-
response activation in trophoblasts in vitro. The transcriptional profile of such cells mimics the 
transcriptome of PE placentas. Pan-mammalian comparative analysis identified DLX5 as a part 
of the human-specific regulatory network of trophoblast differentiation.
Conclusions—Our analysis provides evidence of a true association between disturbed 
imprinting, gene expression and PE. Due to disturbed imprinting, the upregulated DLX5 affects
trophoblast proliferation. Our in vitro model might fill a vital niche in PE research. Human-
specific regulatory circuitry of DLX5 might help to explain certain aspects of PE.
Key Words: preeclampsia/pregnancy; genome-wide analysis; epigenetics; ER stress; 
Trophoblast, Genomic imprinting
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Clinical Perspective
What is new? 
x Unbiased analysis of genome-wide molecular and clinical data identifies DLX5 as an 
imprinted target gene with novel placental function in PE. 
x We observe that DLX5 is paternally imprinted in the human placenta, and its expression 
is dysregulated in PE.
x We provide evidence for a mechanistic coupling between PE and disturbed placental 
imprinting (loss of imprinting) as a causal role in PE. 
x Our data indicate that DLX5 has a role in trophoblast proliferation and differentiation 
(syncytialization). 
x DLX5-induced overexpression in trophoblasts can faithfully model PE in a cell culture 
system, signifying the contribution of a single transcription factor and providing a 
potential cellular model both for further research and for analysis of drugable targets. 
x DLX5 is expressed in the human, but not in mouse trophoblasts, underlying the human 
specificity of PE. Our study highlights the diverged cellular function of DLX5 during 
mammalian embryonic evolution.
What are the clinical implications?  
x Our analysis supports the view that PE is not a single, but a heterogeneous disease, with 
disturbed imprinting commonplace. 
x Unsupervised clustering analysis identified three distinct transcriptomic classes of PE, 
not clustering with the intrauterine growth restriction (IUGR). Our clusters are in 
conjunction with previously suggested classification of PE (early vs late onset), but 
subdivides early onset PE further. 
x Our study identifies an early PE cluster that can be clearly characterized by elevated 
DLX5 levels, disturbed epigenetics and similar clinical manifestation.
x We find that levels of DLX5 correlate with a placenta-derived PlGF circulating 
biomarker. Whether DLX5 will have a utility as a biomarker is unclear as its loss of 
imprinting is not observed in all instances (69% of all PE). 
x Our cellular model has potential for further clinically-related research including analysis
of drugable targets.  
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Preeclampsia (PE) is a complex, heterogeneous syndrome characterized by high blood pressure 
(140/90 mmHg) after the 20th week of pregnancy in association with SURWHLQXULDPJOSHU
24-hour)1. PE is the first sex-specific cardiovascular risk factor2, affecting 2-8% of human 
pregnancies, and remains a leading cause of maternal and perinatal mortality3.  
Despite the considerable research efforts, the etiology of PE is not fully understood. PE is 
assumed to be associated with reduced fetal trophoblast invasion and impaired remodeling of 
maternal spiral arteries leading to poor uteroplacental perfusion. The improper placentation 
process triggers oxidative and endoplasmic reticulum (ER) stress, and results in defective protein 
synthesis in the placenta. As a consequence, dysregulated expression of inflammatory, angio- 
and antiangiogenic factors is observed4 in PE. Currently, the only treatment is delivery, 
pinpointing to the potentially central role of the placenta (or maternal-foetal interaction more 
generally) in the disease5.
The placenta has unique epigenetic features, including low levels of genomic DNA 
methylation and a specific expression pattern of imprinted genes, which are the prime candidates 
to be associated with the evolution of intrauterine development6. As epigenetic disruption of 
imprinted gene was associated with certain diseases, the potential involvement of disturbed 
regulation of imprinted genes in PE has been also intensively discussed7-11.  
Curiously, PE is not confirmed in other mammals, and considered as being human specific (even 
though a possible eclampsia event was observed in a gorilla)12. The human-specificity of PE 
generates real challenges. First, despite intensive research, the genetic background of the human-
specificity and the etiology of PE remain poorly understood. Second, although rodent models 
have been suggested, no animal models have proven suitable.  
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As placentation is a diverse process even among primates13, genes associated preferentially with 
placental expression (e.g. imprinted genes) are potential candidates for understanding human-
specificity. This suggestion is largely centered on the understanding a) that dosage of imprinted
genes can have phenotypic impact, b) that the placenta is a “hotspot” for the activity of imprinted 
genes, and hence c) that loss of imprinting will be likely to affect matters at the maternal-foetal 
interface. 
Despite the abundant speculation that disruption of imprinting and PE might be 
mechanistically coupled, the evidence is at best limited. Indeed, a recent review of the genetics 
of PE14 reports no robust evidence for a mechanistic coupling with imprinting. What evidence 
there has been is circumstantial, often negative or not replicable15-19. A further barrier to effective 
research - until recently20 - has been the lack of a definitive list of genes imprinted in the human 
placenta. 
To get a better understanding of this highly complex disease, we aim at confirming our 
hypotheses a) that PE is not a single, but a heterogeneous disease of the placenta; b) that it is 
associated with improper trophoblast function; c) that epigenetic turbulence can result in 
abnormal expression of imprinted genes, which in turn d) compromise proper maternal foetal 
interaction and contribute to PE; e) specifically in human. Our experimental strategy is based on 
a cross-disciplinary approach that employs the current catalog of human imprinted placental 
genes, combines the generation and analyses of genome-wide molecular data with well-
characterized patient material, followed by experimental validation. We employ molecular, 
cellular technologies and bioinformatic analyses to predict biological processes affected in PE, 
followed by wet-bench validation. We also aimed at establishing an in vitro model to fill a vital 
niche in PE research, explicitly because there is no robust animal model system. Finally, we data-
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mine existing single cell transcriptome data to possibly shed light on the human specific nature 
of PE. 
Methods
Detailed methods are provided in the Data Supplement.
Patients
Microarray data of human placenta and decidua samples were described earlier21. The study also 
consists of placental and decidual tissues from 56 preeclamptic women (PE) and 28 women with 
normotensive and uncomplicated pregnancies described earlier22. The PE group was subdivided 
into PE + IUGR (n = 14) and PE without IUGR (n = 42). Furthermore, the PE group was divided 
into early-onset PE (delivery <34 gestational week) and late-onset 3(GHOLYHU\JHVWDWLRQDO
week). The Regional Committee of Medical Research Ethics in South-Eastern Norway approved 
the study, and all the subjects gave informed written consent.
The healthy (n=5) and PE (n=5) primary trophoblast cells were isolated from human placenta 
samples obtained from HELIOS Klinikum in Berlin. Human placenta sampling was approved by 
the Regional Committee of the Medical Faculty of Charité Berlin. 
Statistics
Data is presented as mean ± SEM (for normally distributed data) or median with inter-quartile 
range (for non-normally distributed data). Normality was assessed by Kolmogorov-Smirnov 
tests. Techniques for each analysis are specified in the figure legends.  
p<0.05 was considered statistically significant.
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Results
Cluster analysis identifies three distinct transcriptome patterns of preeclamptic placenta
To determine which genes have aberrant expression in PE, we sought to first better understand 
whether PE is one disease or many and then to look for genes misregulated across all PE
subtypes. We compared placenta and decidua samples from 24 PE patients and 22 healthy 
women. Nineteen (19/24) PE placental samples generated three distinct molecular groups of PE 
(PE_P1-3) (Fig. 1A), while control samples (16/22) generated two groups (C1, C2). Five (5/24)
PE and four (4/22) healthy placental samples grouped with the opposite cluster. While placental 
PE_P1 and PE_P3 contain samples from early-onset PE, PE_P2 included samples mainly from 
late-onset PE. We did not reveal any significant grouping for the IUGR phenotype. An 
alternative clustering method based on Euclidean distances, identified the same three PE clusters
(Fig. S1A). In contrast to placental samples, the PE and control decidua samples appeared to 
scatter randomly (Fig. S1B), supporting that clinically established PE is a placental, and not a
decidual disorder. The “negative” result for the decidua in addition provides a negative control 
for false/artefactual clustering.
A subset of early onset preeclampsia correlates with clinical symptoms
Is there an association between the PE gene clusters and clinical data? We clustered 36 Patient`s
clinical and biomarker parameters on their relative values (Table S1). Our analysis suggests that
gene expression profile can be related to clinical disease phenotyping, but only to a certain extent
(Fig. 1B and Fig. S2A, B). Besides a related transcriptome, PE_P1 also shared a similar clinical
profile. By contrast, most of the patients from PE_P2 generated a cluster together with PE
samples that had diverse transcriptome, and patients from PE_P3 had a diverse clinical
manifestation.
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We also performed correlation analyses of clinical and gene expression data across all
Control and Patient samples to identify genes associated with any of the clinical phenotype. We 
found correlated gene expression with maternal PlGF (e.g. PAPPA2, SPAG4, ENG and LEP) and
sFlt1 levels (e.g. SPAG4, ENG, ANKRD37 and ERRFI1). Among the imprinted genes, the 
expression of both DLX5 and GATA3 correlated with diastolic BP and anti-correlated with GA
(Fig. S2C). DLX5 also correlated with sEndoglin (positive) and with baby weight (negative) 
markers.
All preeclamptic clusters have disturbed guidance signalling
We then analyzed differentially expressed genes (DEGs) in each PE cluster, compared to control 
samples. Each cluster contained over a thousand unique DEGs with 366 dysregulated genes 
common to all three clusters, (p-value < 0.05) (Fig. 1C and Table S2). To characterize the 
clusters, and find possible interactions, datasets containing 3525, 2634 and 4073 DEGs 
corresponding to PE clusters PE_P1, PE_P2, and PE_P3 respectively, were analyzed using 
Ingenuity Pathway Analysis (IPA) and GOrilla gene ontology tools. Axonal guidance was the top 
pathway in all three PE clusters, supporting the view that disturbed angiogenesis and cell-cell 
communication between endothelial cells and the trophoblasts via the mechanism of axonal 
guidance is a common feature of PE23, 24. Other than this universal property, the three clusters 
exhibited unique features (Fig. S3 and Table S2).
Imprinted genes exhibit differential expression in preeclamptic placenta
Next, we focused on differentially expressed imprinted genes in PE. We used a merged list of 
genes of the Geneimprint database (184 validated and putative human imprinted genes) and the 
recent list of imprinted human placental genes (223, maternal:paternal allelic expression ratio, 
80:20)20 (Table S3). Our analysis identified 150 imprinted/putatively imprinted genes that were 
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dysregulated in at least one of the three PE clusters (p-value <0.05) (Fig. 1D and Table S3). 
Maternally and paternally expressed genes (MEGs and PEGs) were affected according to their 
relative commonality (23%, 59/257 vs 17%, 25/150; Ȥ2=1.9, p-value=0.16) (Fig. 1F and Table 
S3). This was observed also when M/P allelic expression ratios were considered at different 
stringencies (Fig. 1G). The mean expression of MEGs was however significantly downregulated 
compared to PEGs (Fig. 1H). Nevertheless, among the most significantly deregulated genes we 
identified both MEGs (e.g. DLX5, APOBEC2, CD74) and PEGs (e.g. GATA3, CYP2J2) (Fig. 1E, 
F). In our study, the two most significantly dysregulated imprinted genes were GATA3 and DLX5
(p-values <2.51x10-6) and <3.65x10-9, respectively). Further, we focus on DLX5, which is a
MEG in human lymphoblasts and brain25, but its imprinted status in the placenta is not yet 
explored.
DLX5 is upregulated in preeclamptic placenta
We used qRT-PCR to confirm the upregulation of DLX5 in PE placental samples (Fig. S4, B). 
We then confirmed these findings in a second independent patient cohort of 56, compared to 28 
controls. Although DLX5 was significantly upregulated in both early-onset (p-value<0.0001) and 
late-onset (p-value<0.01) PE (Fig. 2A), and in all the three PE clusters, its expression level 
varied between placental samples. Nevertheless, altogether 69% of PE samples (n=56) could be 
associated with DLX5 overexpression. We also confirmed increased DLX5 protein expression in 
PE placenta tissues by Western blotting (Fig. S4C, D). Correlation analysis of gestation age 
(GA) to DLX5 expression in Control or PE placentas excluded GA-related changes in DLX5
differential expression (Fig. S4E). In tissues and cells derived from a pregnancy-related tissue 
panel DLX5 expression was detected in placenta and in trophoblasts, but was less pronounced in
the decidua (Fig. S4F, G). Immunofluorescent staining detected co-expression of DLX5 with 
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cytokeratin-7 (CK7), a trophoblast-specific marker (Fig. 2B). Immunohistochemistry confirmed 
elevated DLX5 protein expression in placental tissues of early-onset PE (Fig. 2C). 
To associate our findings with clinical PE biomarkers, we compared the placental 
expression of DLX5 with the “anti-angiogenic” sFlt1 and sFlt1/PlGF ratio and with “pro-
angiogenic” PlGF concentration in maternal serum26. While there was no significant correlation 
between DLX5 expression and sFlt1 levels, we observed a negative correlation (r=-0.35; p-
value=0.017) with PlGF concentrations, comparing PE and healthy woman (Fig. 2D). This 
observation suggests that placental DLX5 expression is associated with decreased levels of a 
maternal circulating placental biomarker in PE. 
Loss of imprinting results in elevated gene expression of DLX5
To investigate if alterations in the predicted imprinting status of DLX5 could be responsible for 
its overexpression in the PE placentas, we performed a LOI assay27. We measured expression of 
the silenced allele in placental samples carrying the heterozygous DLX5 SNP (rs73708843). 
Primers are provided in Table S4. Of 97 placental tissues, 42 were genotyped as heterozygous 
(43.3%), including 16 control (16.5%) and 26 PE (26.8%) placentas. The mean expression of the 
putatively inactive DLX5 allele was 58% in PE placenta samples when setting the expression of 
the non-imprinted allele for each individual sample 100%. Control samples also exhibited LOI 
but with significantly less frequent (19%) activation of the imprinted DLX5 allele (Fig. 3A, B). 
Sequencing of cDNA through the SNP (rs73708843) on three placenta samples confirms the 
single allelic expression from DLX5 (Fig. 3C). Importantly, we found a correlation (r=0.314; p-
value=0.046) between LOI and DLX5 expression, suggesting that the overexpression phenotype 
of DLX5 was associated with its LOI (Fig. 3D). We also inspected CpG methylation levels at the 
DLX5 locus in PE placental compared to healthy control samples (20 vs 20)28, and identified
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significant CpG hypomethylation in PE samples (Fig. 3E and Table S5). Furthermore, the 
methylation level of several CpGs inversely correlated with DLX5 expression in these samples (8 
vs 8) (Fig. 3F). Collectively, we interpreted our data as the altered methylation at the DLX5
locus in PE results in LOI, and affects gene expression.  
Upregulated DLX5 affects genes associated with cell growth, proliferation, survival and 
movement
To decipher the physiological effect of elevated DLX5 expression on trophoblasts, we stably 
overexpressed the human DLX5 protein in trophoblast cells in vitro. For the overexpression 
studies, we used the Sleeping Beauty transposon-derived expression system29 in SGHPL-4 cells, 
derived from first trimester extravillous trophoblasts (Fig. S5A-C). Immunohistochemistry 
revealed a predominant nuclear localization of DLX5 in the DLX5-overexpressing SGHPL-4 
cells (DLX5High) (Fig. S5D). To observe the global effects of elevated DLX5 expression, we 
performed microarray transcriptome profiling of DLX5High and control (Control) cells. A total of 
3650 DEGs (p-value<0.05; 771 genes at FDR<0.05) were identified upon DLX5 overexpression 
(Fig. S6A and Table S6). IPA revealed significant gene enrichment involved in cardiovascular 
system development and function. The most significant terms describing molecular and cellular 
functions include cellular growth and proliferation, cell death and survival or cellular movement 
and development (Fig. S6B). The top pathways include interferon-, death receptor signalling
and superpathway of cholesterol biosynthesis. Importantly, several affected pathways are 
common between PE placental samples and the in vitro model. These include deregulated axon 
guidance-, IL-8-, neuregulin receptor signalling, TR/RXR, RAR and PCP pathway, antigen 
presentation pathway, unfolded protein response and NRF2-mediated oxidative stress responses 
(Table S6).
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Elevated expression of DLX5 models certain aspects of preeclampsia 
To test how well our DLX5high in vitro model mimics global transcriptional changes in PE, we 
compared transcriptome profiles of Control and DLX5high cells with the three placental PE 
transcriptome clusters (PE_P1-3). Hierarchical clustering of relative gene expression levels of 
Control, DLX5high lines (6 vs 6), PE_P1-3 and healthy placenta samples revealed that the 
transcriptome of DLX5high cells clusters with the three PE groups (PE_P1-3), whereas Control
cells cluster with control placenta samples (Fig. 4A). Additionally, we asked if it was possible to 
correlate transcriptomes according to their DLX5 expression levels (Fig. S7A). Placenta samples 
were ordered according to their DLX5 expression levels. Importantly, the transcriptomes of 
DLX5high PE clustered with cultured DLX5high samples, while the low_DLX5 PE were clustered 
with Control SGHPL-4 cells, suggesting that the overexpression of DLX5 in trophoblasts could 
model certain aspects of PE (Fig. S7B). 
Identifying genes with correlated expression dynamic to DLX5 
As the target genes of the transcription factor DLX5 in placenta are not known, we thought to 
identify genes whose expression is correlated with DLX5. Thus, we subjected a merged dataset 
of our two microarrays (total 58 samples) to weighted gene correlation network analysis 
(WGCNA). We aimed at identifying gene modules of correlated gene expression. This approach 
allowed us to detect several gene modules containing a total of 3,000 genes. Using pairwise 
ranked correlation analysis of 79 genes, associated with DLX5 across 58 samples (Fig. 4B), we 
identified putative targets of DLX5. The list contains several genes, previously associated with 
PE30-35, including genes involved in cell growth, proliferation and differentiation (e.g. GREM2,
KIT, ERRFI1), angiogenesis (e.g. VEGFC, PAPPA2, GPR126), cytokine and growth hormone 
signalling (GBA, CXCR7), immune response (ISG15, HERC5, IFIT1), pregnancy specific 
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proteins (PSG2-4), as well as the paternally imprinted, tissue factor pathway inhibitor-2 (TFPI2), 
involved in regulation of cell invasion and proliferation.  
Upregulation of DLX5 in trophoblasts is associated with disturbed epigenetics
To address the limitations of our initial approach using placental microarray data, we performed 
transcriptome analysis employing RNAseq on freshly isolated, purified human trophoblasts from 
control and PE placentas (5 vs 5). In the PE_T1 trophoblast sample, DLX5 was highly 
upregulated, and we observed 1466 genes commonly dysregulated in both PE_T1 and DLX5high
with 641 genes exhibiting the same pattern of expression, including KIT, SOCS2, KLF5, BEX2,
ERRFI1, as well as DNA methyltransferases (DNMT1 and DNMT3B) (Fig. 4C). In addition to 
common features, PE_T1 sample exhibited further DEGs involved in the regulation of DNA 
methylation and histone modification, such as TET gene family (TET1-3), SETDB1, SIRT1 and 
HDACs, indicating that a subset of PE might be associated with severe epigenetic disturbances. 
As a likely consequence, PE_T1 sample is characterized by the deregulation of several imprinted 
genes (including DLX5), but also potentially mutagenic transposable elements, such as LINE-1 
and SVA36, 37 (Fig. 4D, E). 
Upregulation of DLX5 reduces trophoblast proliferation
The significant increase of DLX5 expression in PE placenta samples prompted us to explore the 
possible mechanism of DLX5 in the pathogenesis of PE. To characterize the DLX5high phenotype 
we have performed several cellular assays, inspired by the Pathway analyses. To determine 
whether the DLX5high phenotype affects trophoblast proliferation, we used time-lapse 
microscopy, and observed reduced cell proliferation of DLX5high cells by 45%, compared to 
control after 48h incubation (Fig. 5A). Significantly, reduced trophoblast proliferation of 
DLX5high was confirmed by a high-throughput sampler cell count and microtiter plate test (MTT) 
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colorimetric assay (Fig. 5B, C). DLX5 overexpression had only a slight, not significant effect on 
cell apoptosis as indicated by scoring apoptotic cells within 48h of incubation (Fig. S8A, B). 
Elevated DLX5 expression affects the metabolic profile of the trophoblast
Cell proliferation, growth and metabolism are tightly linked processes. To determine whether
reduced proliferation was associated with altered metabolism, we monitored metabolic 
parameters in DLX5high cells. We determined extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR), indicators of mitochondrial respiration and glycolytic activity,
respectively (Fig. 5D-F). Compared to control, metabolic profiling detected elevated level of 
ECAR and maximal OCR values, suggesting an accelerated metabolism of DLX5high cells (Fig.
5E, F). Furthermore, DLX5high cells displayed increased spare respiratory capacity (SCR) values,
when compared to Control cells (Fig. 5E). In principle, the increased energetic demand could 
reflect a response to increased stress or cell survival challenges. 
DLX5 expression responds to endoplasmic reticulum stress
Abnormal placentation in PE results in a series of biological stresses. To investigate the potential 
role of DLX5 in stress response, we monitored reactive oxidative species (ROS) production and 
the effect of induced endoplasmic reticulum (ER) stress. While, we did not detect elevated ROS 
production in DLX5high cells (Fig. 5G), DLX5 expression was sensitive to induced ER stress in 
BeWo choriocarcinoma cells, expressing DLX5 at a readily detectable level. In a hypoxia-
reoxygenation challenge assay, DLX5 expression increased significantly upon ER stress in a 
severity-dependent manner (Fig. 5H and Fig. S9A). Furthermore, in our DLX5high transcriptome,
we observed upregulation of several genes involved in the unfolded protein response pathway 
(UPR), associated with ER stress response (Fig. S9B). Importantly, eight of these genes, INSIG1,
SREBF1, HSP90B1, ATF6, MBTPS1, PPP1R15A, XBP1, HSPA2 were also dysregulated in our 
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PE placenta samples (Fig. S9C). While enhanced DLX5 level appears to trigger the cellular 
stress response, DLX5 expression increased with syncytium formation as evidenced by Forskolin 
treatment of BeWo cells, suggesting a potential role of DLX5 during the syncytialization process 
(Fig. S9D).
Dlx5 expression shifts from post-implantation to pre-implantation stage of embryogenesis 
during evolution 
DLX5 is primarily known as a transcription factor regulating morphogenesis and tissue 
homeostasis38-40, and it is mostly characterized during post-implantation embryogenesis. As we 
observed DLX5 is expressed in trophoblast, we sought to monitor its expression pattern in pre-
implantation embryos. We performed comparative single-cell RNAseq data analysis on mouse, 
macaque and human embryos collected at early embryonic developmental stages41-43. In human, 
the expression of DLX5 appears at the transition from E4 to E5 stage (Fig. 6A), rendering DLX5
one of the earliest expressed genes in the human trophoectoderm (Fig. 6B). Curiously, Dlx5
expression is shifted toward late trophoectoderm in macaque (Fig. 6C) and is not detectable in 
murine pre-implantation embryos (Fig. 6A). To check if Dlx5 is expressed at later stages of 
placenta development in mice, we performed placental immunostaining (E14.5 and E15.5) in 
Dlx5-LacZ+/- animals. Although we observed a weak positive LacZ staining in the Dlx5-LacZ+/- 
animals on the external muscular layer of the placenta, the signal was not significantly different 
from the control (Fig. S10), suggesting that Dlx5 is not involved in murine placentation.
Surprisingly, only 33 common trophectoderm marker genes could be identified between mouse 
and human. In human, among the early TE markers, DLX5 exhibits the highest activation of 
expression, followed by RGS13, NDRG2, ODAM, SLC38A1 as well as ID3, HAND1, DLX3,
GCM1 (Fig. 6D). Among the genes expressed differentially in human vs mouse preimplantation 
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embryos, GREM2, GPR126, USP53 and EFNB3 are putative targets of DLX5 (Fig. 5B).
Intriguingly, GREM2, GPR126, USP53 are also upregulated in PE (Fig. 1B), suggesting that the 
dysregulation of maternally expressed DLX5 and its putative targets might explain certain 
features of the human-specific nature of PE. The genes expressed in the same clusters might 
share transcriptional networks (Fig. 6E, F and Table S7). Interestingly, the maternally, but not 
the paternally expressed genes form characteristic clusters during human embryogenesis.
Discussion
There certainly has been much speculation that disturbed regulation of imprinted genes might be 
involved in the development of PE, however prior evidence could not establish significant 
association between them14-19. Here we provide robust evidence for a mechanistic coupling 
between PE and disturbed placental imprinting. Our experimental strategy first aimed at 
identifying differentially expressed genes (DEGs) in PE placentas by analysing genome-wide 
molecular data on well-characterized patient material. The list of DEGs was than intersected with 
the current catalog of human imprinted placental genes. Employing the novel set of genes could 
clarify certain important issues regarding the long-term debated list of imprinted genes in the 
human placenta. Our strategy revealed several potential candidates, supporting the hypothesis 
that disturbed imprinting and PE could be indeed associated. Our candidate list included 
imprinted genes that were previously associated with PE, however their expression deregulation 
could not be convincingly connected to LOI15. CYP2J2 and CD74 belonged to a category of 
genes whose deregulation was already implicated in PE, but their epigenetic disturbance was not 
considered as a contributing factor21, 22. Our strategy also identified genes that were not yet 
implicated in PE, and their imprinted status is poorly explored in placenta (APOBEC2, GATA3,
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DLX5). Curiously, APOBEC2, an enzyme involved in controlling DNA-based parasites, such as 
viruses and transposable elements, appeared on the list of MEGs deregulated in all three clusters 
of PE. The most significantly affected imprinted genes in PE were GATA3 and DLX5. GATA3
could be an excellent candidate for further research, as it was previously reported to inhibit 
trophoblast invasion44, thought to be a key process in PE. Here, we focus on DLX5, a 
transcription factor of the Distal-less homeobox protein family. DLX5 is involved in 
developmental processes of the limb, brain and bone in both mice and human38, 45. However, its 
placental function is not characterized. 
We show that DLX5 is expressed in human villous and extravillous trophoblast, and is 
controlled by imprinting. DLX5 is upregulated in ~70% of PE patients. The upregulation of 
DLX5 in PE is associated with its “leaky” expression from the imprinted allele (LOI). In contrast 
to previous studies27, 46, we find a correlation between expression of an imprinted gene and its
LOI in PE. Our data mining28, 47 also reveals differential CpG methylation of the DLX5 locus in 
PE placentas. Although our analysis does not rule out other mechanisms of DLX5 expression 
regulation, such as transcriptional or microRNA regulation, we provide evidence of an
association between disturbed imprinting gene expression and PE.
The spatial and temporal regulation of cell proliferation and differentiation is crucial for 
successful pregnancy. The first half of gestation is characterized by a series of trophoblast 
proliferation and differentiation processes, building mature villi and extravillous structures48, 49.
Upregulation of DLX5 resulted in reduced (~45%) proliferation of the trophoblast. Curiously, 
the decreased trophoblast cell proliferation was accompanied by increased oxygen consumption. 
Why might poorly proliferating trophoblast cells require an accelerated metabolism? We 
hypothesized that DLX5 overexpression could sensitize trophoblasts to stress. As a result, the 
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cells require increased metabolic activity to overcome this state-of-affairs. Indeed, the 
transcriptome analysis of DLX5high trophoblast revealed several affected pathways acting as 
stress inducers, such as unfolded protein response pathways, increased interferon-, and death 
receptor signalling. Thus, the upregulation of DLX5 could be a factor contributing to an 
accelerated placenta “ageing” process and elevated ER stress, resulting in stressed 
syncytiotrophoblast and consequently increased shedding of inflammatory factors into the 
maternal circulation50, 51. While enhanced DLX5 level triggers the cellular stress response, DLX5 
expression increases with syncytium formation, suggesting a role of DLX5 in regulating the 
syncytialization. Our single cell transcriptome data mining of human preimplantation embryos 
establishes DLX5 as a key marker of trophectoderm differentiation. We propose that DLX5 is 
involved in regulating a delicate balance between proliferation and differentiation processes of 
the trophoblast. A disturbance of this key process has been previously associated with PE52, 53.  
In contrast to trophoblasts, DLX5 overexpression is associated with enhanced cell 
proliferation in various cancer cells54-56. Thus, DLX5 might affect proliferation either negatively 
or positively during early development or in cancer, respectively. The response to overexpressed 
DLX5 possibly depends on cell type specific target genes.  Either way, DLX5 appears to be a 
key gene in determining the developmental decisions of trophoblast cells. 
We modeled the effect of DLX5 upregulation in an in vitro system, overexpressing DLX5 
in SGHPL-4 trophoblast cells (DLX5high). Since artificial, exogenous overexpression of a gene in 
cells could alter normal cellular function due to accumulation of unprocessed proteins, we asked 
how faithfully DLX5high cells mimic PE. Importantly, the transcriptome of DLX5high cells 
resembled that of the PE transcriptomes, and several dysregulated pathways were commonly 
seen both in vitro (DLX5high) and in vivo (PE samples). Thus, the DLX5high phenotype can model 
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several features of PE in vitro, in a cell culture system, signifying the impact of the deregulated 
DLX5 in the pathogenic phenotype of PE.  
Given the barriers put towards analysis of PE by its human specificity, our in vitro model 
system has a considerable potential for downstream analyses. Nevertheless, our study does not 
suggest that there could be a single explanation to PE. We identified three distinct transcriptomic 
clusters of PE placenta (PE_P1-3). That the clusters could be related to previously established 
categories of PE, such as early-/late-onsets of PE57, supports the view that PE is a heterogeneous 
placental disease, and does indeed come in several discrete forms. While PE_P2 matches late-
onset PE placentas, PE_P1 and PE_P3 can be considered as subdivisions of early-onset PE. The 
uncovered heterogenic nature of PE would call for validating a panel of subclass-specific 
biomarkers for future diagnostic procedures. The DLX5 overexpression phenotype is detectable 
in all the three clusters, but is most pronounced in PE_P1/2. Levels of DLX5 correlated with 
placenta-derived PlGF circulating biomarker. Whether DLX5 will have a utility as a biomarker is 
unclear as its loss of imprinting was not observed in all instances (69% of PE). Importantly, 
while the PE_P2/3 clusters have no clear clinical pattern, PE_P1 patients exhibit characteristic 
clinical phenotypes. Nevertheless, more samples need to be analyzed to securely relate the 
characteristics of the PE_P1 cluster to clinical disease phenotyping.
Our RNAseq data analysis revealed that a subset of PE is connected to disturbed 
epigenetic gene regulation. The global epigenetic turmoil is likely associated with the observed 
differential expression of genes regulating DNA methylation, resulting in the deregulation of 
transposable retroelements (REs) and imprinted genes. Curiously, the mechanisms of regulating 
imprinting and repressing REs by DNA methylation share several common features58. In fact, 
genomic imprinting is speculated to be a by-product of the genome’s defense mechanisms 
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against retroviruses and REs59, 60. Curiously, a domesticated RE-derived gene (Syncytin-1), 
implicated to have a key role in placental development61-63 has been associated with PE64, 65.
Here, in a subset of PE, we observed the reactivation of the human-specific L1_HS and SVA-F
elements, capable of transposition in the human genome37, 66.  
Besides trophoblast, dysregulation of DLX5 expression in other tissues has been reported 
to contribute to diseases. Downregulation of DLX5 in endometrial glands could also complicate 
early stages of pregnancy that could later manifest in IUGR or PE67. LOI of the maternally 
expressed DLX5 in lymphoblastoid cells contributes to Rett syndrome (RTT), a disorder 
associated with GABAergic dysfunction68, 69. Dysregulation of DLX5 impairs the differentiation 
of GABAergic neurons70. Curiously, GABA can increase hCG secretion in human placenta71,
indicating possible placenta–brain endocrine interactions regulated by imprinting. By contrast to 
Rett syndrome, we do not detect differential expression of DLX6 in PE, suggesting that the 
dysregulation of DLX5 in PE is not associated with expressional changes of DLX6 (not 
regulated by imprinting). We propose that DLX5 and DLX6 are regulated differently in brain 
and placenta. 
DLX5 is expressed in the human, but not in mouse trophoblast. Comparative single cell 
transcriptome analysis revealed a differential expression of DLX5 between human, macaque and 
mouse preimplantation embryogenesis, highlighting the diverged cellular function of DLX5 
during mammalian embryonic evolution. While the DLX5 gene is highly conserved across 
different mammalian species (>95% exon sequence similarity in human, macaque and mouse), 
its upstream, 2-10kb (potential regulatory) region is much faster evolving (>80% and <10% 
sequence similarity between human vs macaque and between human vs mouse, respectively). 
Indeed, despite of the conserved coding structure, DLX5 expression appears to be gradually 
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shifted toward earlier developmental stages during mammalian evolution. While DLX5 is not 
expressed in preimplantation embryos in mice, its expression peaks at the stage of TE and 
ICM/epiblast separation, marks TE committed cells, and is regulated by imprinting in human. In 
addition to DLX5, we could identify further differentially expressed genes between human and 
mice TE. Among these genes, GREM2, GPR126, USP53 and EFNB3 are also putative targets of 
DLX5, suggesting that the function of a DLX5 regulated circuitry has been redefined during 
mammalian evolution. Importantly, GREM2, GPR126, USP53 are also upregulated in PE, and 
thus might be also associated with the human-specific nature of PE.
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Figures Legends
Figure 1. Gene expression analysis of preeclamptic and healthy placenta samples.
(A) Hierarchical clustering analysis of microarray data identified three PE groups in placenta: 
PE_P1 (blue), PE_P2 (yellow), and PE_P3 (green) and two control groups: C1 and C2 (gray, 
dashed). (Control placenta n = 22, PE placenta n = 24). The onset of PE (by gestational age at 
delivery) for each sample is indicated. The PE+IUGR samples are indicated by a star (*). (B)
Clustering analysis of clinical data - Heatmap representing pairwise correlation between Patients 
based on the clinical data (Suppl. Mat, Table S1). Hierarchical cluster dendrogram was 
calculated using ranked correlation and complete linkage method on relative values from the 
clinical variables (n = 36). Height of dendrograms represents the Euclidian distance. (C) Venn 
diagram of differentially expressed genes (DEGs) in three PE clusters (DEG on p-value < 0.05). 
Top up- (red) and downregulated (blue) genes for each cluster are shown. (D) Imprinted genes in 
PE. Heatmap representing differential expression of imprinted genes in the three PE clusters vs 
controls (DEG p-value < 0.05). Log2-fold change of differential expression of maternally (E) and 
paternally (F) expressed genes (MEGs and PEGs), in all PE cases (DEG p-value < 0.05). 
Colored are genes with log2-IROGFKDQJHUHGDQG-0.5 (blue). (G) Distribution of 
differentially expressed MEGs and PEGs in PE according to different criteria for maternal to 
paternal allelic expression ratio (M[%] – P[%]): 60-40, 70-30, as well as 90-10. (H) Wilcoxon 
test on the mean log2-fold change expression of differentially expressed MEGs and PEGs in PE. 
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Figure 2. DLX5 is upregulated in PE placenta.  
(A) Quantitative PCR confirmed increased DLX5 mRNA level in placentas of a second PE 
cohort (values are as mean ± SEM; Control: 1.053 ± 0.0745, n = 28; EO-PE+IUGR: 1.447 ± 
0.066, n = 9; LO-PE+IUGR: 1.71 ± 0.238, n = 5; EO-PE: 1.532 ± 0.08, n = 20; LO-PE: 1.304 ±
0.09, n = 22) (*p < 0.05; **p < 0.005; ***p < 0.0005; ANOVA, Bonferroni's multiple 
comparisons test). (B) Double immunofluorescence staining of term human placenta tissue 
indicated nuclear expression and co-localization of DLX5 to the cytokeratin 7 (CK7), a 
trophoblast-specific marker. The DLX5 staining was positive in the nucleus of both villous and 
extravillous trophoblasts. (C) Immunohistochemistry staining on placental villous tissue from 
healthy pregnancy (Early Control, GA 31 and 34 weeks) and PE (GA 31 and 34 weeks) for 
human DLX5 confirmed increased DLX5 protein expression in early-onset PE placenta. (D) 
Correlation of DLX5 expression and placental biomarker. Placental DLX5 expression 
significantly negatively correlated to the serum PlGF in the PE group but not in controls.
(Control n = 27, PE n = 48, Spearman rank correlation). 
Figure 3. Loss of imprinting (LOI) of DLX5 in PE placenta.  
(A) Analysis of mean LOI levels for DLX5 in healthy and PE placenta samples. Values are 
presented as a mean ± SEM of LOI (Control: 0.1943 ± 0.04765, n = 16; Early-onset PE: 0.5661 
± 0.08516, n = 12, Late-onset PE: 0.6349 ± 0.08437, n = 14) (**p < 0.001, ***p < 0.0001; one-
way ANOVA, Bonferroni's multiple comparisons test). (B) Distribution (number) of DLX5 
heterozygocities exceeding particular LOI. (C) Allelic expression analysis of the imprinted 
DLX5 in placenta samples exhibiting the allele-specific expression, but no LOI. cDNA of the 
heterozygous placenta samples for the SNP (rs73708843) were sequenced. (D) LOI correlated 
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with DLX5 expression in placenta (p = 0.046, Spearman rank correlation). (E) CpG methylation 
of DLX5 locus. Log2-fold change of CpG methylation level in PE (Control, n = 20; Early-onset 
PE n = 20). Hypomethylated CpG sites are shown (DMR at adj.p-YDOXH(F) Pairwise 
Spearman rank correlation of CpG methylation and DLX5 expression in placenta (Control, n = 8; 
Early-onset PE n = 8; FDR p-value: *p < 0.05, **p < 0.01). 
Figure 4. Intersection of PE transcriptomes with the DLX5high transcriptome. 
(A) Hierarchical clustering (Spearman rank correlation, average linkage) and bootstrapping 
(1000 replicates) of the transcriptomes of SGHPL-4 cells with PE Cluster PE_P1, PE Cluster 
PE_P2 and PE Cluster PE_P3 transcriptomes (Placenta PE) and control placenta samples 
(Placenta control). The equal number of control placenta samples to the number of samples in 
each PE cluster was chosen randomly. (B) Weighted gene co-expression network analysis 
(WGCNA) across 58 samples gave several modules containing a total of ~ 3000 genes. 
Identification of DLX5 target genes in placenta and trophoblast cells. Clustered pairwise 
correlation matrix of identified 79 genes across 58 samples (Spearman rank correlation, 
threshold 0.6 and -0.55, p-value < 0.05, Euclidian distance). (C) A comparison between the log2-
fold change of the differentially expressed genes in trophoblast sample PE_T1 and genes 
differentially expressed upon DLX5 overexpression in SGHPL-4 trophoblast cell line. 641 genes 
heaving the same differential expression pattern were common in both datasets. (D) and (E) 
Relative expression of transposable LINE1 and SVA elements in control trophoblast samples and 
PE sample PE_T1. In PE_T1 the young members of the TE families L1PA3, L1PA2, L1HS, 
SVA-E and SVA-F are upregulated (*p < 0.05, ***p < 0.005, Kolmogorov-Smirnov (KS) test,
Benjamini and Hochberg's (BH) false discovery rate (FDR)).
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Figure 5. DLX5 decreases SGHPL-4 cell proliferation. 
(A) DLX5high cells are less proliferative compared to WT cells as indicated by scoring dividing 
cells over 48h of incubation. After 48h of incubation cell proliferation of DLX5high cells (39.58 ± 
5.34) is reduced by 45% as compared to WT (72.92 ± 4.49) (***p = 0.001, ****p < 0.0001; 2-
way $129$%RQIHUURQL
VPXOWLSOHFRPSDULVRQVWHVW71)ĮDWFRQFQJPOVOLJKWO\
decreased cell proliferation in both DLX5high and WT cell (not significant). (B) DLX5high cells 
exhibited decreased cell proliferation (n = 6, median 524.5, IQR: 343.8-843) as compared to WT 
(n = 6, median 1320, IQR: 679.8-2955) confirmed by cell count HTS assay (***p < 0.001; Mann 
Whitney test). (C) MTT viability assay confirmed decreased cell proliferation in DLX5high cells 
(DLX5high median 0.1883, IQR: 0.0454-0.242 vs. WT median 0.3319, IQR: 0.2226-0.3565) 
(****p < 0.0001; Mann Whitney test). (D) Effect of DLX5 on mitochondrial respiration in 
SGHPL-4 cells. OCR was measured under basal conditions followed by the sequential addition 
of oligomycin (0.75μM), FCCP (1μM), and antimycin A (1μM) + Rotenone (0.1μM) in WT (n = 
6) and DLX5high cells (n = 6). Data is normalized to the cell number. (E) Individual parameters 
for basal respiration (WT vs DLX5high: 43.901 ± 1.705 vs 66.082 ± 3.213), maximal respiration 
(WT vs DLX5high H: 109.226 ± 3.913 vs 162.244 ± 6.431), ATP production (WT vs DLX5high:
34.266 ± 1.105 vs 46.415 ± 2.2), proton leak (WT vs DLX5high: 9.635 ± 1.307 vs 20.85 ± 1.687), 
non-mitochondrial OCR (WT vs DLX5high: 18.72 ± 2.989 vs 34.247 ± 5.773) and reserve 
capacity (WT vs DLX5high: 65.325 ± 3.381 vs 90.866 ± 5.455) were extracted from the assay (*p 
< 0.05, ***p < 0.001, ****p < 0.0001; 2-Way ANOVA, Bonferroni's multiple comparisons test). 
(F) Mean basal ECAR level in WT and DLX5high cells (DLX5high median 26.27, IQR: 24.27-
36.35 vs. WT median 22.38, IQR: 17.05-26.99) (**p = 0.01; Mann Whitney test). (G) ROS 
production in WT and DLX5high cells measured by FACS. Data is presented as a mean 
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fluorescent intensity (MFI) of the fluorescent signal from the dichlorodihydrofluorescein (DCF) 
oxidized by ROS. DCFH-DA diffuses into the cell, becomes deacetylated by cellular esterases to 
non-fluorescent DCFH, which is next oxidized to fluorescent DCF by ROS. (H) DLX5 
expression level upon induction of ER stress in BeWo cells. 20N – normoxia, 5/20 HR and 1/20 
HR - cyclic condition of 6 hour of incubation in 5%/20% O2 and 1%/20% O2. Quantification of 
DLX5 level upon induction of ER stress indicates significant upregulation of its expression (*p <
0.01; Kruskal-Wallis test, Dunn's multiple comparisons test).  
Figure 6. DLX5 expression in human, macaque and mouse early embryonic development.  
(A) Violin plots display the expression levels of DLX5 during different stages of human, 
macaque and mouse early embryonic development. In humans, DLX5 starts to be expressed at 
E4/E5 stage of development. In macaque, DLX5 is expressed at E6 stage. Dlx5 is not expressed 
in mouse pre-implantation embryo. (B) Single cell transcriptome analysis of human pre-
implantation embryo reveals TE-specific DLX5 expression. t-SNE analysis on human 353 single 
cells from E4-E5 stages where inner cell mass (ICM) and trophectoderm (TE) split from 
Morulae. We defined clusters of cell populations to identify genes expressing exclusively in 
those clusters. We defined the cell type for each cluster according to the known markers. (C) 
Single cell transcriptome analysis of macaque pre-implantation embryo demonstrates enriched 
DLX5 expression in the late TE (*****p = 2.602E-12, ****p = 1.387E-06; Wilcoxon test). (D) 
Comparative analysis between human and mouse TE markers. For human TE markers, shown 
are genes with log2-fold change > 3. ICM – Inner cell mass, PE – Primitive endoderm, TE – 
Trophectoderm. Single cell transcriptome analysis of human embryogenesis for maternally (E)
and paternally (F) expressed genes. Clustering analysis of imprinted genes expressed during 
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early (oocyte, zygote, 2-cell and 4-cell stage), mid (8-stage, Morulae) embryogenesis and late 
blastocyst (179/257 maternally expressed genes, 86/150 paternally expressed genes). 






